| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $2.21 | - | - |
| Q1'26 | $1.90 | $1.80 | -5.1% |
| Q4'25 | $1.99 | $1.94 | -2.3% |
| Q3'25 | $2.24 | $2.30 | +2.5% |
| Q2'25 | $1.99 | $2.04 | +2.7% |
| Q1'25 | $1.67 | $1.86 | +11.2% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $1.1B | - | - |
| Q1'26 | $1.0B | $1.0B | +0.7% |
| Q4'25 | $1.0B | $1.0B | -0.0% |
| Q3'25 | - | $1.1B | - |
| Q2'25 | - | $1.0B | - |
| Q1'25 | - | $942M | - |
Market Data
ALLE is currently trading at $130.94, giving Allegion plc a market cap of 11.21B and a P/E ratio of 17.7. Today's range spans $129.54–$131.39, with shares opening at $130.41 and moving up $0.51 (0.4%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 54/100.
Over the past year ALLE has traded between $125.00 and $183.11 - the current price is +4.8% off the 52-week low and -28.5% from the high.
Macro sensitivity explains some of ALLE's bearish setup (23/100, SELL) - at 11.21B in Industrials market cap, interest rate shifts, currency moves, or commodity price changes can create fundamental headwinds that compound the technical deterioration. Sentiment: neutral (54/100). Price: $130.94 (near 52-week lows). The current P/E ratio stands at 17.7. Annual range: $125.00–$183.11. The question for investors is whether the macro driver is transient or structural - because the answer determines whether this is a tradeable dip or a deeper re-rating.
The current SELL phase for ALLE (23/100) at $130.94 (near 52-week lows) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at 54/100 (neutral) confirms that news flow is not providing a counternarrative. At 11.21B in Industrials capitalization, ALLE has the liquidity for institutional exits to be orderly — but orderly doesn't mean shallow within the $125.00–$183.11 range.
Most recent articles, ranked by recency (click to expand).
Sentiment gathered from recent headlines